A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia. Issue 10 (3rd October 2018)

• Record Type: Journal Article
• Authors: Torrebadell, Montserrat; Díaz-Beyá, Marina; Kalko, Susana G.; Pratcorona, Marta; Nomdedeu, Josep; Navarro, Alfons; Gel, Bernat; Brunet, Salut; Sierra, Jorge; Camós, Mireia; Esteve, Jordi
• Is Part Of: Leukemia & lymphoma. Volume 59:Issue 10(2018)
• Page Start: 2394
• Page End: 2404
• Publication Date: 2018-10-03
• Subjects: AML -- GEP -- intermediate-risk; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2017.1422859
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: In intermediate-risk cytogenetic acute myeloid leukemia (IRC-AML) patients, novel biomarkers to guide post-remission therapy are needed. We analyzed with high-density arrays 40 IRC-AML patients who received a non-allogeneic hematopoietic stem-cell transplantation-based post-remission therapy, and identified a signature that correlated with early relapse. Subsequently, we analyzed selected 187 genes in 49 additional IRC-AML patients by RT-PCR. BAALC, MN1, SPARC and HOPX overexpression correlated to refractoriness . BAALC or ALDH2 overexpression correlated to shorter overall survival (OS) (5-year OS: 33 ± 8.6% vs. 73.7 ± 10.1%, p = .006; 32 ± 9.3% vs. 66.4 ± 9.7%, p = .016), whereas GPR44 or TP53INP1 overexpression correlated to longer survival (5-year OS: 66.7 ± 10.3% vs. 35.4 ± 9.1%, p = .04; 58.3 ± 8.2% vs. 23.1 ± 11.7%, p = .029). A risk-score combining these four genes expression distinguished low-risk and high-risk patients (5-year OS: 79 ± 9% vs. 30 ± 8%, respectively; p = .001) in our cohort and in an independent set of patients from a public repository. Our 4-gene signature may add prognostic information and guide post-remission treatment in IRC-AML patients.